AGIO
AgiosDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Positive clinical readouts or a value-accretive partnership that materially de-risks programs and meaningfully extends runway could push shares toward the bull target (~+40% vs anchor).
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.7.
What can break
Clinical trial failure or safety signal
Momentum
93
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.08 · Bull $5.19 · Bear $2.60
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $42.38
Why
Momentum93 · Δ7d -1.7
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
93
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.7
Δ21d
+10.3
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 92.8 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$2.22B
Beta
0.91
Shares Out
59.47M
P/E (TTM)
3.8
P/S (TTM)
35.74
P/FCF (TTM) · Derived
-5.67
Rev YoY
+137.7%
EPS YoY
+8.5%
Gross Margin
+82.1%
Op Margin
-1061.8%
Net Debt
-$814.22M
Current Ratio
14.19
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology